NASDAQ · Biotechnology

TELO (TELO) Stock

$1.21 -3.20% NASDAQ: TELO Healthcare

Valuation

MetricValue
Price$1.21
Market Cap$41.60M
P/E Ratio-3.97
P/B Ratio7.51
P/S Ratio0.00
EPS (TTM)$-0.33
52-Week High$3.10
52-Week Low$1.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-166.67%
ROA-142.86%
ROCE-183.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0$-1.0M$-4.0M$-12.0M$-11.0M
Net Profit$0$-1.0M$-13.0M$-17.0M$-10.0M
EPS$0.00$-0.03$-0.44$-0.56$-0.33
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$5.0M$1.0M$7.0M
Total Liabilities$0$1.0M$1.0M$1.0M$1.0M
Cash$0$0$0$1.0M$7.0M
Borrowings$0$1.0M$0$0$0

Latest News

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model ACCESS Newswire · Jun 15, 2026 Telomir Names Andriy Mushak as Fractional Chief Financial Officer MT Newswires · Jun 9, 2026 Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease ACCESS Newswire · May 20, 2026 Telomir Says US FDA Clears Investigational New Drug Application for Telomir-Zn to Treat Triple-Negative Breast Cancer MT Newswires · Apr 30, 2026 Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer ACCESS Newswire · Apr 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$-4.0M$-5.0M$-4.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$0$0$1.0M$6.0M
Free Cash Flow$0$0$-4.0M$-5.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-10.29%
Quick Ratio7.00
Interest Coverage—
Return 1Y8.09%
Return 3Y—
Return 5Y—

Ownership

Insiders Held35.10%
Institutions Held3.28%
Institutions Float Held5.05%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC995,3732026-03-31
Blackrock Inc.289,1982026-03-31
Geode Capital Management, LLC249,0862026-03-31
Vanguard Fiduciary Trust Co135,5412026-03-31
Millennium Management Llc129,0602026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
GNTAGenenta Science S.p.A. $1.50 -5.66% -3.98 $28.72M 0.00%

About TELO

TELO is led by CEO Erez Aminov, employs 1 people, headquartered in US, publicly traded since 2019.

TELO stock trades at $1.21 with a market capitalization of $41.60M. The stock is valued at a price-to-earnings (P/E) ratio of -3.97, price-to-book of 7.51, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.05 and $3.10, and currently trades 61.0% below its 52-week high.

On profitability, TELO generates a return on equity (ROE) of -166.67%, return on capital employed of -183.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides